Abstract:
INTRODUCTION:The introduction of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung cancer (NSCLC) with EGFR+ mutations. However, most patients develop resistance, with the result that median progression-free survival (PFS) iŝ12 months. Combining EGFR-TKIs with other agents, such as bevacizumab, is a promising approach to prolonging remission. This systematic review and network meta-analysis (NMA) were undertaken to assess available evidence regarding the benefits of first-line combination therapy involving EGFR-TKIs in patients with advanced NSCLC. METHODS:Literature searches were performed using relevant search terms. Study-level pseudo-individual patient-level data (IPD) were recreated from digitized Kaplan-Meier curve data, using a published algorithm. Study IPD were analyzed using both the proportional hazards and the acceleration failure time (AFT) survival models, and it was concluded that the AFT model was most appropriate. An NMA was performed based on acceleration factors (AFs) using a Bayesian framework to compare EGFR-TKIs and chemotherapy. RESULTS:Nine randomized controlled trials were identified that provided data for EGFR-TKI therapy in patients with EGFR+ tumors. These included studies of afatinib (n=3), erlotinib (n=3), erlotinib plus bevacizumab (n=1) and gefitinib (n=2). Erlotinib plus bevacizumab produced the greatest increase in PFS compared with chemotherapy, with 1/AF being 0.24 (95% credible interval [CrI] 0.17, 0.34). This combination also produced greater increases in PFS compared with EGFR-TKI monotherapy: 1/AF versus afatinib, 0.51 (95% CrI 0.35, 0.73); versus erlotinib, 0.53 (95% CrI 0.39, 0.72) and versus gefitinib, 0.46 (95% CrI 0.32, 0.66). All three EGFR-TKI monotherapies prolonged PFS compared with chemotherapy; estimates of treatment effect ranged from 1/AF 0.53 (95% CrI 0.48, 0.60) for gefitinib to 1/AF 0.46 (95% CrI 0.40, 0.53) for erlotinib. There was no evidence for differences between EGFR-TKI monotherapies, as all 95% CrIs included the null value. CONCLUSION:Although data for erlotinib plus bevacizumab came from a single Phase 2 study, the results of the NMA suggest that adding bevacizumab to erlotinib may be a promising approach to improving the outcomes achieved with EGFR-TKI monotherapy in patients with advanced EGFR+ NSCLC.
journal_name
Onco Targets Therjournal_title
OncoTargets and therapyauthors
Batson S,Mitchell SA,Windisch R,Damonte E,Munk VC,Reguart Ndoi
10.2147/OTT.S134382subject
Has Abstractpub_date
2017-05-05 00:00:00pages
2473-2482issn
1178-6930pii
ott-10-2473journal_volume
10pub_type
杂志文章abstract:Objective:The phenomenon that cancer cells avidly exhibit glycolysis with lactate secretion and decrease in mitochondrial activity under aerobic conditions is known historically as the Warburg effect. Rho GTPase-activating protein 4 (ARHGAP4) is an important negative regulator of the Rho signaling pathway that was asso...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S207560
更新日期:2019-06-28 00:00:00
abstract::Bladder cancer (BC) is a common urinary system tumor with high aggressiveness, and it results in relatively high mortality due to a lack of precise and suitable biomarkers. In this study, we applied the weighted gene coexpression network analysis method to miRNA expression data from BC patients, and screened for netwo...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S146479
更新日期:2017-11-22 00:00:00
abstract:Background:Although several long non-coding RNAs (lncRNAs) have been found to be involved in gastric cancer tumorigenesis, the more comprehensive contributions of lncRNAs to gastric cancer require further investigation. Here, we identify a cytoplasmic lncRNA, LINC01485, which promotes tumor growth and migration in gast...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S257151
更新日期:2020-08-21 00:00:00
abstract:AIM:To investigate the significance of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER)2, and HER3 expression on survival outcomes in Chinese gastric cancer patients. MATERIALS AND METHODS:Formalin-fixed, paraffin-embedded specimens from 121 patients who underwent gastrectomy at Sh...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S70922
更新日期:2014-12-16 00:00:00
abstract:BACKGROUND:The purpose of this research was to investigate the relationship between epidermal growth factor receptor (EGFR) mutations and the response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS:A total of 266 patients with stage IIIB or IV NSCLC who received platin...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S63665
更新日期:2014-07-01 00:00:00
abstract:Background:Renal cell cancer (RCC) is one of the most lethal malignancies of the kidney in adults. mTOR (mammalian target of rapamycin) signaling pathway plays a pivotal role in RCC tumorigenesis and progression and inhibitors targeting the mTOR pathway have been widely used in advanced RCC treatment. Therefore, it is ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S266095
更新日期:2020-10-15 00:00:00
abstract:BACKGROUND:Two types of epidermal growth factor receptor (EGFR) mutations in exon 19 and exon 21 (ex19del and L858R) are prevalent in lung cancer patients and sensitive to targeted EGFR inhibition. A resistance mutation in exon 20 (T790M) has been found to accompany drug treatment when patients relapse. These three mut...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S84938
更新日期:2015-06-22 00:00:00
abstract::Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%-3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the c...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S141053
更新日期:2018-08-06 00:00:00
abstract::Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficacy of systemic thera...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S221354
更新日期:2019-12-24 00:00:00
abstract::Background and aims: HOXD antisense growth-associated long noncoding RNA (HOXD-AS1) was reported to be upregulated in various cancers, such as gastric cancer, hepatocellular carcinoma, colorectal cancer, and glioma. Here, we conducted a meta-analysis and The Cancer Genome Atlas data review to investigate the clinicopa...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S184303
更新日期:2018-11-05 00:00:00
abstract:Purpose:To evaluate the capability of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG-PET/CT) to predict the clinical response of metastatic lymph node (mLN) to definitive chemoradiotherapy (dCRT) and guide personalized radiation dose in esophageal squamous cell carcinoma (ESCC) patien...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S160456
更新日期:2018-07-25 00:00:00
abstract:Objective:Cumulative data from clinical trials suggest that Lin28 may contribute to poor survival in breast cancer patients. The purpose of this study was to investigate the relationship between Lin28 expression and breast cancer patients' clinicopathological parameters. Methods:Data from a total of 291 breast cancer ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S190328
更新日期:2019-02-08 00:00:00
abstract:PURPOSE:This study aimed to explore the molecular mechanisms associated with bisphosphonate (BP)-related osteonecrosis of the jaw (ONJ) in patients with multiple myeloma (MM). METHODS:The gene expression profile GSE7116 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) fro...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S88463
更新日期:2015-09-22 00:00:00
abstract:Background:The non-receptor tyrosine kinase Fyn-related kinase (FRK) has been reported to affect cell proliferation in several cancer types. However, its effect on the proliferation of clear cell renal cell carcinoma (ccRCC) remains largely unknown. Purpose:The objective of this study was to investigate the expression...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S199238
更新日期:2019-04-10 00:00:00
abstract:Objective:To clarify the role and mechanism of GABPB1-AS1 in renal cell carcinoma. Methods:We collected 48 pairs of tumor and adjacent normal tissues from patients with clear cell renal cell carcinoma (ccRCC). Both 786-o and caki-1 ccRCC cell lines were transfected with GA-binding protein transcription factor subunit ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S257275
更新日期:2020-07-12 00:00:00
abstract:Background:Several intracellular signaling pathways that are deregulated during hepatocarcinogenesis might constitute potential targets for hepatocellular carcinoma (HCC) therapy. The aim of this study was to test the potential synergic antitumor effect of salirasib and sorafenib in a diethylnitrosamine (DEN)-induced H...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S176903
更新日期:2018-10-17 00:00:00
abstract:AIM:To retrospectively evaluate the safety and efficacy of ultrasound-guided percutaneous microwave ablation (MWA) combined with simultaneous transarterial chemoembolization (TACE) in the treatment of patients with advanced intrahepatic cholangiocarcinoma (ICC). METHODS:All patients treated with ultrasound-guided perc...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S84764
更新日期:2015-05-26 00:00:00
abstract::Fibroblast growth factor receptor (FGFR) family includes four highly conserved receptor tyrosine kinases. Particularly, FGFR2 has been identified as a potential target for tyrosine kinase inhibitor (TKI) treatment. Except for immunohistochemistry and fluorescence in situ hybridization, next-generation sequencing (NGS)...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S218796
更新日期:2019-11-06 00:00:00
abstract::Colorectal cancer continues to be an important public health concern, despite improvements in screening and better systemic chemotherapy. The integration of targeted therapies in the treatment of colon cancer has resulted in significant improvements in efficacy outcomes. Angiogenesis is important for tumor growth and ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:
更新日期:2009-02-18 00:00:00
abstract:Background and aim:Studies suggest that antiviral therapy performed after curative resection improves the postoperative prognosis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), but the evidence has been contradictory. The aim of this meta-analysis was to assess the effect of antiviral therapy with n...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S150281
更新日期:2017-11-10 00:00:00
abstract::Ocular sebaceous carcinoma (SC) is an exceedingly rare but aggressive malignancy that can impair patients' visual acuity or even cause tumor-specific mortality. This tumor usually mimics chronic benign eyelid lesions, thus leading to delayed diagnosis, thereby causing high recurrence and metastasis. Ophthalmologists s...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S162073
更新日期:2018-06-27 00:00:00
abstract:Purpose:The aim of this study was to investigate the antitumor effect of chidamide in combination with bortezomib on gastric cancer cell lines. Materials and Methods:First, the sensitivity and IC50 values of chidamide and bortezomib in several gastric cancer cell lines (MGC-803, BGC-823, SGC-7901, and MKN45) were meas...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S240721
更新日期:2020-05-06 00:00:00
abstract:Background:Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The Southwest Oncology Group (SWOG) 1406 study evaluated the efficacy of vemurafenib in combination with irinotecan and cetuximab for simultaneous inhibition of epiderma...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S180845
更新日期:2019-01-08 00:00:00
abstract:Purpose:To evaluate the association between tertiary Gleason pattern 5 (TGP5) and biochemical recurrence (BCR) in patients with prostate cancer (PCa) with a Gleason score (GS) of 7 after radical prostatectomy (RP). Patients and methods:This retrospective study identified 350 patients who received RP and were graded as...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S218001
更新日期:2019-09-02 00:00:00
abstract:Introduction:Microfibril-associated protein 2 (MFAP2) is an extracellular matrix protein that interacts with fibrillin to modulate the function of microfibrils. MFAP2 has been reported to play a significant role in obesity, diabetes, and osteopenia, and has been shown to be upregulated in head and neck squamous cell ca...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S160831
更新日期:2018-07-12 00:00:00
abstract::Aberrant promoter methylation of RUNX3 has been reported in several tumors including human breast cancer (BC). However, the association between RUNX3 hypermethylation and incidence of BC remains elusive. In this study, a detailed literature search was performed in Medline and Google Scholar for related research public...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S77828
更新日期:2016-08-26 00:00:00
abstract:OBJECTIVE:High-mobility group protein 2 (HMGA2) and epithelial-mesenchymal transition (EMT)-associated proteins play key roles in cancer progression and metastasis. However, the clinical significance of HMGA2 and its relationship with EMT markers in nasopharyngeal carcinoma (NPC) is unclear. This study aimed to assess ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S74397
更新日期:2015-01-17 00:00:00
abstract:OBJECTIVE:To evaluate the efficacy and safety of bortezomib-based vs non-bortezomib-based post-transplantation therapy in patients with multiple myeloma. METHODS:Data of relevant randomized controlled trials assessing the effect of bortezomib as post-transplantation consolidation or maintenance therapy was obtained th...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S84828
更新日期:2015-06-15 00:00:00
abstract:PURPOSE:To explore whether changes in tumor size impact survival in advanced non-small-cell lung cancer (NSCLC) after target therapy, especially in patients with evaluation of stable disease (SD), and to review the applicability of the Response Evaluation Criteria in Solid Tumors (RECIST) criteria in target therapy. P...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S38441
更新日期:2012-01-01 00:00:00
abstract::Angiogenesis (the growth of new blood vessels) is essential in most of the body's physiological processes, such as in the normal functioning of the endometrium during and after the menstrual cycle. Vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) are the mostly expressed angiogenic factors,...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S132558
更新日期:2017-09-19 00:00:00